Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival gains in HR+/HER2– MBC trials yet to be seen in real world

Publish date:: December 4, 2019

Key clinical point: Survival rates for the most common form of metastatic breast cancer did not change over a decade.

Major finding: Median overall survival after diagnosis was 2.0 years, and did not differ with time.

Study details: Retrospective analysis of data on 2,197 patients with HR+/HER2– metastatic breast cancer treated in British Columbia.

Disclosures: No specific study funding was disclosed. No authors disclosed potential conflicts of interest.

Citation:

Le D et al. Cancer 2019 Nov 21. doi: 10.1002/cncr.32631.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,